On the other hand, osteoclasts no longer maintained a pro-myeloma effect on activated RPMI-8226 (16.59% with 300 μM BzATP, p = 0.0073 versus 237% with 0 μM BzATP) but could be prevented with P2X7 receptor antagonist (135.8% with 1 μM AZ11645373) (Figure 4C). The gene discussed is P2RX7; the disease is plasma cell myeloma.